CardioIQ Insulin Resistance Panel

Your fasting blood sugar can look perfectly normal for a decade while your body quietly loses the ability to process sugar efficiently. The earliest sign of this shift is not a change in blood sugar itself. It is a change in how hard your pancreas has to work to keep blood sugar in range. This panel measures that effort directly.

By pairing two markers of insulin output with a calculated resistance score, the CardioIQ Insulin Resistance Panel detects the metabolic strain that precedes type 2 diabetes and raises heart disease risk, often years before a standard glucose test flags anything abnormal.

What This Panel Reveals

The panel answers a single, specific question: is your body already struggling to manage blood sugar, even if your blood sugar numbers still look fine? It does this by measuring two different signals from the pancreas and combining them into a single score.

The first signal is the amount of insulin circulating in your blood after an overnight fast. In a healthy body, a small amount of insulin is enough to keep blood sugar steady. When cells start ignoring insulin's signal (a state called insulin resistance), the pancreas compensates by pumping out more. Elevated fasting insulin is one of the earliest detectable signs of metabolic trouble.

The second signal is C-peptide, a protein fragment released in equal amounts every time the pancreas makes insulin. C-peptide matters because it is not cleared by the liver the way insulin is. Roughly half of the insulin your pancreas secretes gets removed during its first pass through the liver, so a blood insulin level can underestimate how much your pancreas is actually producing. C-peptide bypasses that problem, giving a more stable and accurate picture of total pancreatic output.

The third component, the Insulin Resistance Score, integrates both measurements into a single number that estimates where you fall on the spectrum from insulin sensitive to insulin resistant. Rather than interpreting two lab values separately, the score translates them into an actionable classification.

Why This Combination Matters More Than a Single Test

Fasting insulin alone is useful but imperfect. Insulin levels fluctuate with meals, stress, sleep, and even the time of morning. A single fasting insulin measurement can miss the bigger picture, especially in people whose livers clear insulin at different rates. A person with aggressive hepatic insulin clearance can have a normal fasting insulin level while their pancreas is working overtime.

C-peptide fills that gap. Because it is not extracted by the liver, it reflects total insulin secretion rather than what happens to survive into the bloodstream. In a large cross-sectional analysis from the National Health and Nutrition Examination Survey (NHANES), elevated C-peptide was independently associated with increased cardiovascular mortality, even after adjusting for traditional risk factors. A study of over 2,000 adults followed for more than five years found that each standard deviation increase in fasting C-peptide was associated with a 39% higher risk of cardiovascular events.

The calculated score adds interpretive power. Instead of asking you to compare two numbers against separate reference ranges and guess what the combination means, it classifies your overall insulin resistance status. This makes the panel more actionable than ordering either test alone.

How to Read Your Results Together

The most useful way to interpret this panel is pattern recognition. The table below shows the four most common result patterns and what each one means for your metabolic health.

The second pattern (elevated insulin, elevated C-peptide, moderate to high score) is the most common finding in people on the path toward type 2 diabetes. A prospective analysis from the Insulin Resistance Atherosclerosis Study (IRAS) showed that individuals in the highest quartile of insulin resistance had a significantly greater rate of progression to diabetes over five years compared to those in the lowest quartile, even when baseline glucose was normal.

The third pattern is particularly valuable. Without C-peptide, a person with high hepatic insulin clearance could receive falsely reassuring results. The panel catches this blind spot.

When Results Can Be Misleading

Acute illness, significant physical stress, or use of corticosteroids can temporarily raise both insulin and C-peptide, producing a false picture of insulin resistance. If you have been sick, had surgery, or are taking prednisone or similar medications, wait at least two to three weeks before testing.

Kidney function also matters. C-peptide is cleared by the kidneys, so reduced kidney function can elevate C-peptide levels independently of insulin production. If your kidney markers (creatinine or cystatin C) are abnormal, interpret C-peptide with caution.

Exogenous insulin use will suppress C-peptide while raising insulin levels, creating a mismatch that does not reflect natural pancreatic function. This panel is designed for people not currently on insulin therapy.

The Connection to Heart Disease

Insulin resistance is not just a diabetes precursor. It is an independent cardiovascular risk factor. The Botnia Study, which followed over 4,000 individuals for more than seven years, found that people with insulin resistance had roughly a threefold higher risk of coronary heart disease compared to insulin-sensitive individuals, regardless of whether they ever developed diabetes.

Elevated fasting insulin promotes arterial damage through several pathways: it raises triglycerides, lowers HDL cholesterol, increases inflammatory markers, and shifts the body toward a blood-clotting state. A meta-analysis of 17 prospective studies involving over 48,000 participants found that elevated fasting insulin was associated with a 50% increased risk of cardiovascular events in non-diabetic individuals.

C-peptide carries its own signal. Research from the Women's Health Initiative, following over 16,000 postmenopausal women, showed that women in the highest quartile of C-peptide had significantly elevated risks of both coronary heart disease and stroke, independent of BMI and other metabolic markers.

Tracking Over Time

A single set of results is a snapshot. Serial testing every six to twelve months transforms this panel into a trend line that reveals whether your metabolic trajectory is improving, stable, or worsening. This is where the panel's value compounds.

If you make dietary changes, increase physical activity, improve sleep, or lose weight, repeat testing shows whether those interventions are actually reducing your pancreatic workload. A study in Diabetes Care showed that lifestyle intervention reduced fasting insulin levels by roughly 25% within six months in participants with impaired glucose tolerance, well before any meaningful change in HbA1c (a measure of average blood sugar over three months).

Tracking C-peptide alongside insulin also reveals whether improvements are real or cosmetic. For example, a medication that lowers blood sugar without reducing insulin resistance will not change C-peptide levels. The panel tells you whether the underlying problem is being addressed, not just masked.

What to Do with Your Results

If all three markers are normal and the score is low, you are insulin sensitive. Retest annually to confirm the trend holds, especially if you have a family history of type 2 diabetes or heart disease.

If your score is moderate, you are in the compensation phase. Your pancreas is working harder than it should. This is the ideal window for intervention. The Diabetes Prevention Program (DPP) trial demonstrated that structured lifestyle changes (150 minutes per week of moderate exercise plus 7% body weight loss) reduced the risk of progressing to type 2 diabetes by 58% in people with early metabolic dysfunction. Retest in three to six months to confirm the intervention is working.

If your score is high, consider adding a full lipid panel, HbA1c, and liver enzymes (ALT, AST) to assess the downstream effects of insulin resistance on your heart and liver. A conversation with a physician experienced in metabolic health is appropriate. Repeat testing in three months to track response to any changes you make.

For any abnormal result, adding a fasting glucose and HbA1c helps place your insulin resistance in the context of actual blood sugar control. If glucose is still normal while insulin and C-peptide are elevated, you have caught the problem early, exactly when it is most reversible.